NeuroSense Advances Toward Key Regulatory Milestones with Strengthened Data Package and Near-Term Alzheimer's Readout
PrimeC New Data to Be Presented at AD/PD™ 2026 Conference [Yahoo! Finance]
PrimeC New Data to Be Presented at AD/PD™ 2026 Conference
NeuroSense Therapeutics (NRSN) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $14.00 price target on the stock.
JAMA Neurology Publishes Results from PARADIGM Phase 2b Trial of PrimeC in ALS Demonstrating Meaningful Clinical Outcomes and Biological Activity [Yahoo! Finance]